[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-420326-105":59,"doc-detail-420326-en":131},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":124,"head_meta":126,"extra_data":128,"updated_unix":130},105,"en","inetetamab-based-regimens-for-patients-with-her2-positive-metastatic-breast-cancer-areal-world-retrospective-study","Inetetamab-Based Regimens for Patients with HER2-Positive Metastatic Breast Cancer - AReal-World Retrospective Study","","Real-world outcomes and safety of inetetamab-containing regimens were evaluated in patients with HER2-positive metastatic breast cancer. A retrospective review included salvage-treated patients from December 2020 to April 2024, including those with brain metastases. Progression-free survival served as the primary endpoint in the total population. Among 90 patients (data cut-off June 1, 2024), median PFS was 12.0 months; ORR was 46.6% and DCR 92.2%. Toxicity was tolerable, with diarrhea the most frequent grade 3/4 adverse event.",{"@graph":69,"@context":123},[70,84,106],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":35,"@type":76,"position":81},"https://docshare.wps.com/document/healthcare/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/inetetamab-based-regimens-for-patients-with-her2-positive-metastatic-breast-cancer-areal-world-retrospective-study/420326/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/inetetamab-based-regimens-for-patients-with-her2-positive-metastatic-breast-cancer-areal-world-retrospective-study/420326.png","ImageObject",300,407,{"name":92,"@type":93},"nayy☆","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-08","2026-09-28",true,{"@type":102,"interactionType":103,"userInteractionCount":105},"InteractionCounter",{"@type":104},"ViewAction",13,{"@type":107,"mainEntity":108},"FAQPage",[109,115,119],{"name":110,"@type":111,"acceptedAnswer":112},"What was the primary endpoint in this study of inetetamab-based regimens?","Question",{"text":113,"@type":114},"Progression-free survival (PFS) in the total population was the primary endpoint.","Answer",{"name":116,"@type":111,"acceptedAnswer":117},"How many patients were included, and what were the key efficacy results?",{"text":118,"@type":114},"Ninety patients were included. Median PFS was 12.0 months, ORR was 46.6%, and DCR was 92.2%.",{"name":120,"@type":111,"acceptedAnswer":121},"What safety findings were reported for inetetamab-containing regimens?",{"text":122,"@type":114},"The toxicity was described as tolerable, and diarrhea was the most frequent grade 3 or 4 treatment-related adverse event (12.2%).","https://schema.org",{"og:url":83,"og:type":125,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":127,"canonical":83},"index,follow",{"doc_id":129,"site_id":62},420326,1790788525,{"code":4,"msg":5,"data":132},{"doc_id":129,"user_id":133,"nickname":92,"user_avatar":134,"doc_module":4,"category_id":34,"category_name":35,"doc_title":65,"doc_description":67,"doc_content":135,"file_id":136,"file_url":137,"file_type":138,"file_size":139,"view_count":105,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":140,"language":141,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":142,"faqs":143,"seo_title":144,"seo_description":67,"update_tm":145,"read_time":146,"preview_page_count":4},962090893153,"https://ap-avatar.wpscdn.com/davatar_9964176cb1d06d4a9deccf72a44ae3dc","Breast Cancer: Targets and Therapy  \n Open Access Full Text Article  \nORIGINAL RESEARCH  \nInetetamab-Based Regimens for Patients with HER2-Positive Metastatic Breast Cancer: AReal-World Retrospective Study  \nLiping Chen, Jiayi Huang , Xuelian Chen, Xiaofeng Lan, Lin Song, Xiaofeng Xie, Xue Bai, Caiwen Du  \nDepartment of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital & Shenzhen Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Shenzhen, Guangdong, People’s Republic of China  \nCorrespondence: Caiwen Du, Email [dusumc@aliyun.com](dusumc@aliyun.com)  \n\n| Background: Inetetamab is a Chinese-origin recombinant anti-HER2 monoclonal antibody. Herein, we assessed the efficacy and safety of inetetamab-containing regimens in patients with HER2-positive metastatic breast cancer (MBC) .\u003Cbr>Patients and Methods: We retrospectively reviewed the medical records of patients with HER2-positive MBC who received inetetamab-containing regimens as a salvage treatment in metastatic setting from December 2020 to April 2024. The primary endpoint was progression-free survival (PFS) in the total population (TP) . Patients with brain metastases were also included. Secondary endpoints were objective response rate (ORR), disease control rate (DCR), and safety.\u003Cbr>Results: At the data cut-off date of June 1, 2024, a total of 90 patients were included in this analysis. Median follow-up duration was 7.2 months (IQR 3.6–13.1) . The median PFS was 12.0 months (95% confidence interval [CI] 7.3 to 17.0 months) in the TP. The median PFS in the subgroup with brain metastases reached 10.0 months (95% CI 5.9 to NA months) . The ORR was 46.6%(42/90), and the DCR was 92.2%(83/90) . The most frequently combined chemotherapy was vinorelbine (83/90,92.2%) . The most frequently concomitant targeted drug was pyrotinib (70/90,77.8%) . The median PFS not reached for first-line, 15.9 months (95% CI 11.9 to NA months) for second-line, and 5.9 months (95% CI 4.4 to 12.2 months) for third-line or later therapy. Cox univariate and multivariate analyses demonstrated that lines of treatment were the only significant predictive factor for PFS (first- and second-line vs third-line or above: 15.9 vs 5.9 months, p=0.0021) . The toxicity was tolerable. The most frequent grade 3 or 4 treatment-related adverse events were diarrhea (12.2%) . Conclusion: Inetetamab offers a promising option and a manageable safety profile for HER2-positive MBC who pretreated with multiple-line therapies. Meanwhile, inetetamab plus small-molecule TKIs regimens shows good anti-tumor efficacy for MBC with brain metastases, which deserves further validation in a larger group trial.\u003Cbr>Keywords: inetetamab, HER2-positive metastatic breast cancer, pretreated, safety |\n| --- |\n| Introduction\u003Cbr>According to GLOBOCAN 2020, Breast cancer (BC) is the most common cancer among women in China and abroad.1 Human epidermal growth factor receptor 2 (HER2)-positive patients account for approximately 15–20% of breast cancers.2 HER2-positive BC represented a more aggressive subtype, with higher tumor grade, more recurrence, and poorer prognosis in the absence of systemic therapy.3–5 Although huge progresses have been achieved in treating HER2-positive BC, metastatic disease remains incurable. Nearly all the metastatic breast cancer (MBC) patients will suffer from disease progression after first-line treatment with trastuzumab.6,7 In the last decades, the development of multiple antiHER2 agents, including monoclonal antibodies, tyrosine kinase inhibitors (TKIs) and antibody drug conjugates (ADCs),8 has significantly improved the survival of patients with HER2-positive BC. However, in China, a huge proportion of patients with HER2-positive MBC have to abandon treatment due to high expenditure on drugs like ADCs which are not included in medical insurance.9 Continuous inhibition of the HER2 pathway offers a survival benefit to MBC patients treate","cbCaisJkNiy1826H","https://ap.wps.com/l/cbCaisJkNiy1826H","pdf",1152514,11,"English","# Introduction\n# Patients and Methods\n# Results\n## Primary endpoint\n## Secondary endpoints\n# Discussion\n# Conclusion","[{\"question\":\"What was the primary endpoint in this study of inetetamab-based regimens?\",\"answer\":\"Progression-free survival (PFS) in the total population was the primary endpoint.\"},{\"question\":\"How many patients were included, and what were the key efficacy results?\",\"answer\":\"Ninety patients were included. Median PFS was 12.0 months, ORR was 46.6%, and DCR was 92.2%.\"},{\"question\":\"What safety findings were reported for inetetamab-containing regimens?\",\"answer\":\"The toxicity was described as tolerable, and diarrhea was the most frequent grade 3 or 4 treatment-related adverse event (12.2%).\"}]","Inetetamab-Based Regimens for Patients with HER2-Positive Metastatic Breast Cancer - AReal-World Retrospective Study | PDF",1790620471,28]